Product Description
Cefdinir is used to treat certain infections caused by bacteria such as bronchitis (infection of the airway tubes leading to the lungs); pneumonia; and infections of the skin, ears, sinuses, throat, and tonsils.. Cefdinir is in a class of medications called cephalosporin antibiotics. It works by killing bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a698001.html)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Bangladesh | Chile | Colombia | Ecuador | Egypt | India | Indonesia | Ireland | Jordan | Korea | Lebanon | Mexico | Pakistan | Peru | Philippines | Portugal | Saudi Arabia | Sweden | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Highest Development Phases
Phase 1: Abscess|Anthrax|Blepharitis|Bronchitis, Chronic|Carbuncle|Cellulitis|Cystitis|Erysipelas|Escherichia coli Infections|Folliculitis|Haemophilus Infections|Hidradenitis|Inflammation|Influenza, Human|Klebsiella Infections|Laryngitis|Lymphadenitis|Lymphangitis|Mastitis|Otitis Media|Otitis Media, Suppurative|Paronychia|Pharyngitis|Pneumonia|Pneumonia, Bacterial|Proteus Infections|Pyelonephritis|Pyoderma|Scarlet Fever|Sinusitis|Surgical Wound Infection|Tonsillitis|Urethritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20132519 | P1 |
Recruiting |
Escherichia coli Infections|Influenza, Human|Tonsillitis|Urethritis|Blepharitis|Abscess|Folliculitis|Pyelonephritis|Mastitis|Klebsiella Infections|Bronchitis, Chronic|Otitis Media|Cystitis|Pneumonia|Paronychia|Surgical Wound Infection|Lymphadenitis|Haemophilus Infections|Carbuncle|Sinusitis|Proteus Infections|Pyoderma|Pharyngitis|Erysipelas|Cellulitis |
None |
|
| CTR20130963 | P1 |
Active, not recruiting |
Bronchitis, Chronic|Lymphangitis|Urethritis|Escherichia coli Infections|Tonsillitis|Erysipelas|Blepharitis|Klebsiella Infections|Paronychia|Influenza, Human|Abscess|Mastitis|Folliculitis|Otitis Media, Suppurative|Pyelonephritis|Cystitis|Hidradenitis|Cellulitis|Sinusitis|Carbuncle|Anthrax|Pyoderma|Pneumonia|Proteus Infections|Pharyngitis |
None |
|
| CTR20202701 | P1 |
Not yet recruiting |
Sinusitis|Otitis Media|Pyoderma|Pyelonephritis|Escherichia coli Infections|Klebsiella Infections|Cystitis|Tonsillitis|Influenza, Human|Haemophilus Infections|Pneumonia, Bacterial|Proteus Infections|Pharyngitis|Lymphadenitis|Scarlet Fever|Laryngitis|Bronchitis, Chronic |
None |
|
| CTR20211160 | P1 |
Not yet recruiting |
Escherichia coli Infections|Otitis Media, Suppurative|Anthrax|Sinusitis|Haemophilus Infections|Carbuncle|Inflammation|Cystitis|Klebsiella Infections|Paronychia|Pneumonia|Bronchitis, Chronic|Lymphangitis|Proteus Infections|Pharyngitis|Abscess|Pyoderma|Pyelonephritis|Cellulitis|Influenza, Human|Hidradenitis|Scarlet Fever|Erysipelas|Folliculitis |
None |